Now showing items 1-1 of 1

    • Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma 

      Phillips, Adrienne A.; Fields, Paul A.; Hermine, Olivier; Ramos, Juan C.; Beltran, Brady E.; Pereira, Juliana; Wandroo, Farooq; Feldman, Tatyana; Taylor, Graham P.; Sawas, Ahmed; Humphrey, Jeffrey; Kurman, Michael; Moriya, Junji; Dwyer, Karen; Leoni, Mollie; Conlon, Kevin; Cook, Lucy; Gonsky, Jason; Horwitz, Steven M.; 0761-009 Study Group (Ferrata Storti Foundation, 2019-05)
      Acceso abierto
      Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase ...